The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells

British Journal of Pharmacology

Volumn 167, Issue 7, 2012, Pages 1431-1447

  Pinzon Daza M L ^a,b   Garzon R ^b   Couraud, P O ^c   Romero, I ^d   Weksler, B ^e   Ghigo, D ^a,f   Bosia, A ^a,f   Riganti, C ^a,f  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c INSTITUT COCHIN   (France)

^d OPEN UNIVERSITY   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

ATP binding cassette transporters; blood brain barrier; central nervous system tumours; doxorubicin; liposomes; low density lipoproteins receptor; nitric oxide; statins

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; COMPACTIN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; NITRIC OXIDE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA KINASE; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; CELL LINE; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOSOMES; LOVASTATIN; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRITES; RECEPTORS, LDL; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIMVASTATIN;

EID: 84868660382     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02103.x     Document Type: Article

References (49)

1. Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB, (2008). Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kB ligand through modulation of NF-kB pathway. Int J Cancer 123: 1733-1740.
2. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J, (2006). Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target 14: 97-105.
3. Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J, et al,. (2011). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci 18: 1444-1448.
4. Bababeygy SR, Polevaya NV, Youssef S, Sun A, Xiong A, Prugpichailers T, et al,. (2009). HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model. Anticancer Res 29: 4901-4908.
5. Bauer B, Hartz AMS, Miller DS, (2007). Tumor necrosis factor α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 71: 667-675.
6. Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, et al,. (2009). RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma-a phase II study. BMC Cancer 9: 308-318.
7. Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I, Mowery SA, et al,. (2010). ABC and SLC transporter expression and pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. Mol Pharm 7: 1057-1068.
8. Declèves X, Amiel A, Delattre JY, Scherrmann JM, (2006). Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 6: 433-445.
9. Deelen JF, Loscher W, (2007). The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13: 1663-1674.
10. Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E, Pescarmona G, et al,. (2008). RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol Cancer Res 6: 1607-1620.
11. Glas M, Koch H, Hirschmann B, Jauch T, Steinbrecher A, Herrlinger U, et al,. (2007). Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 72: 302-307.
12. Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, et al,. (2011). TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release 154: 93-102.
13. Hartz AMS, Bauer B, Fricker G, Miller DS, (2007). Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-α and lipopolysaccharide. Mol Pharmacol 69: 462-470.
14. Hawkins BT, Sykes DB, Miller DS, (2010). Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 30: 1417-1425.
15. Huerta S, Chilka S, Bonavida B, (2008). Nitric oxide donors: novel cancer therapeutics. Int J Oncol 33: 909-927.
16. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM, (2008). Multi-functional nanocarriers to overcome tumour drug resistance. Cancer Treat Rev 34: 592-602.
17. Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaele D, et al,. (2007). Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8: 793-799.
18. Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, et al,. (2011). A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release 149: 196-205.
19. Laufs U, Liao JK, (2000). Targeting Rho in cardiovascular disease. Circ Res 87: 526-528.
20. Liao K, Laufs U, (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118.
21. Mercer RW, Tyler MA, Ulasov IV, Maciej S, (2009). Targeted therapies for malignant glioma. BioDrugs 23: 25-35.
22. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, et al,. (2006). Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 317: 1246-1253.
23. Monnaert V, Betbeder D, Fenart L, Bricout H, Lenfant AM, Landry C, et al,. (2004). Effects of I- and hydroxypropyl- I-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier. J Pharmacol Exp Ther 311: 1115-1120.
24. 6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 29: 379-388.
25. Nakata S, Tsutsui M, Shimokawa H, Yamashita T, Tanimoto A, Tasaki H, et al,. (2007). Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kB pathway. Arterioscler Thromb Vasc Biol 27: 92-98.
26. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM, (2007). Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328: 86-94.
27. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H, (2010). Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 23: 75-93.
28. Provencher SW, (1982). A constrained regularization method for inverting data represented by linear algebraic or integral equations. Comput Phys Commun 27: 213-227.
29. Rattan R, Giri S, Singh AK, Singh I, (2003). RhoA negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain derived transformed cell lines: negative regulation of IKKa. Free Radic Biol Med 39: 1037-1050.
30. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, et al,. (2005). Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65: 516-525.
31. Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, Bosia A, (2006). Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer 119: 17-27.
32. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, et al,. (2008). Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 74: 476-484.
33. Riganti C, Voena C, Kopecka J, Corsetto P, Montorfano G, Enrico E, et al,. (2011). Liposome-encapsulated doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 8: 683-700.
34. Rikitake Y, Liao JK, (2005). Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232-1235.
35. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, et al,. (2005). Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36: 2251-2257.
36. Robey RW, Massey PR, Amiri-Kordestani L, Bates SE, (2010). ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem 10: 625-633.
37. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A, (2008). Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14: 971-976.
38. Salkeni MA, Lynch JL, Otamis-Price T, Banks WA, (2009). Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways. J Neuroimmune Pharmacol 4: 276-282.
39. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN, (2007). Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24.
40. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M, (2010). Double impact on pglycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer 126: 2025-2035.
41. Siflinger-Birnboim A, Del Vecchio PJ, Cooper JA, Blumenstock FA, Shepard JM, Malik AB, (1987). Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol 132: 111-117.
42. Tai LM, Loughlin AJ, Male DK, Romero IA, (2009). P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-β. J Cereb Blood Flow Metab 29: 1079-1083.
43. Troost J, Lindenmaier H, Haefeli WE, Weiss J, (2004). Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol 66: 1329-1332.
44. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, et al,. (2005). Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19: 1872-1874.
45. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J, (2011). Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Control Release 154: 103-107.
46. Wong HL, Bendayan R, Rauth AM, Wu XY, (2004). Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 93: 1993-2008.
47. Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, et al,. (2011). Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res 30: 74-82.
48. Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, Birnbaum Y, (2008). The role of eNOS, iNOS, and NF-kB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 295: H343-H351.
49. Zhang W, Ling V, (2000). Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol 184: 17-26.